Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GAO critical of Taxol deal

The National Institutes of Health, which collaborated with Bristol-Myers (BMY) to develop Taxol, did not exercise its authority to ensure that

Read the full 217 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE